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ABSTRACT
Background: Observational studies often infer hepatic de novo
lipogenesis (DNL) by measuring circulating fatty acid (FA) markers;
however, it remains to be elucidated whether these markers
accurately reflect hepatic DNL.
Objectives: We investigated associations between fasting hepatic
DNL and proposed FA markers of DNL in subjects consuming their
habitual diet.
Methods: Fasting hepatic DNLwas assessed using 2H2O (deuterated
water) in 149 nondiabetic men and women and measuring the
synthesis of very low-density lipoprotein triglyceride (VLDL-TG)
palmitate. FA markers of blood lipid fractions were determined by
gas chromatography.
Results: Neither the lipogenic index (16:0/18:2n–6) nor the SCD
index (16:1n–7/16:0) in VLDL-TG was associated with isotopically
assessed DNL (r = 0.13, P = 0.1 and r = −0.08, P = 0.35,
respectively). The relative abundances (mol%) of 14:0, 16:0, and
18:0 in VLDL-TG were weakly (r ≤ 0.35) associated with DNL,
whereas the abundances of 16:1n–7, 18:1n–7, and 18:1n–9 were
not associated. When the cohort was split by median DNL, only
the abundances of 14:0 and 18:0 in VLDL-TG could discriminate
between subjects having high (11.5%) and low (3.8%) fasting hepatic
DNL. Based on a subgroup, FA markers in total plasma TG,
plasma cholesteryl esters, plasma phospholipids, and red blood cell
phospholipids were generally not associated with DNL.
Conclusions: The usefulness of circulating FAs as markers of
hepatic DNL in healthy individuals consuming their habitual diet
is limited due to their inability to discriminate clearly between
individuals with low and high fasting hepatic DNL. Am J Clin
Nutr 2019;109:260–268.
Keywords: de novo lipogenesis, fatty acids, metabolism, human,
triglycerides, lipogenic index, SCD, palmitoleic acid
Introduction
In humans, the process whereby excess nonlipid precursors
(e.g., sugars and protein) are synthesized to fat, de novo
lipogenesis (DNL), primarily occurs in the cellular cytoplasm of
the liver. It requires acetyl-CoA as a precursor and the principal
building blocks to produce palmitoyl-CoA, the major quantitative
product (1, 2). It is often suggested that enhanced DNL is related
to metabolic diseases including nonalcoholic fatty liver disease
(NAFLD), cardiovascular disease, and type 2 diabetes (TD2) (3–
6), although it is unclear if this is a cause or an effect.
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TABLE 1 Characteristics of study participants1
All subjects (n = 149) Low DNL (n = 75) High DNL (n = 74)
Male/female 64/85 31/44 33/41
Age, y 47.3 ± 8.4 47.3 ± 7.9 47.7 ± 8.9
BMI, kg/m2 27.3 ± 3.9 26.4 ± 3.6 28.1 ± 4.1∗∗
Waist, cm 92 ± 13 88 ± 12 95 ± 13∗∗∗
Body fat, % 34 ± 7 32 ± 7 35 ± 7∗∗
Visceral fat, kg 1.1 (0.5–2.0) 0.8 (0.4–1.9) 1.4 (0.6–2.3)∗
Homeostatic model assessment of insulin resistance 2.5 (1.9–3.5) 2.4 (1.7–2.9) 3.0 (2.1–4.6)∗∗∗
Glucose, mmol/L 5.2 ± 0.5 5.2 ± 0.5 5.3 ± 0.5
Insulin, mU/L 11.1 (9.2–13.6) 10.3 (7.7–12.2) 12.7 (9.8–20.1)∗∗∗
Total cholesterol, mmol/L 5.2 ± 1.0 5.2 ± 1.0 5.3 ± 0.9
HDL cholesterol, mmol/L 1.4 ± 0.4 1.4 ± 0.4 1.3 ± 0.4∗
Nonesterified fatty acids, μmol/L 512 ± 183 522 ± 187 503 ± 181
Triglyceride, mmol/L 1.0 (0.7–1.9) 0.9 (0.6–1.3) 1.5 (0.9–2.1)∗∗∗
DNL, % 6.5 (3.8–11.5) 3.8 (1.8–5.2) 11.5 (8.5–16.5)∗∗∗
1Data are presented as means ± SDs or medians (IQR). ∗P < 0.05; ∗∗P < .001; ∗∗∗P < 0.001 low DNL compared with high DNL. Differences were
analyzed using the t-test or Mann–Whitney U-test. Low/High DNL groups based on lower/higher than median DNL in all subjects. BMI, body mass index;
DNL, de novo lipogenesis.
Hepatic DNL can be directly assessed in vivo in humans
using stable-isotope tracers, where the appearance of the stable-
isotope label [from deuterated water (2H2O) or [13C]acetate] is
measured in very low-density lipoprotein (VLDL) triglyceride
(TG) palmitate. Fasting hepatic DNL has been reported to be up
to ∼10% in healthy adults (7–11) and significantly higher (up to
22%) in individuals with insulin resistance/NAFLD (7–9, 12).
There is a marked increase in the contribution of DNL
to VLDL-TG after consumption of a high-carbohydrate diet
when assessed by the linoleate-dilution method and 13C-acetate
infusion (13). Intervention studies comparing low- with high-
carbohydrate diets attribute observed changes in fatty acid (FA)
composition of blood lipid fractions to DNL without having
measured DNL (14). Although observational studies commonly
use FA composition and/or FA ratios in various circulating lipid
fractions to infer hepatic DNL (3–6), it has yet to be demonstrated
FIGURE 1 Distribution of liver fat in males and females. DNL, de novo
lipogenesis.
that these FA markers are reflective of hepatic DNL during
ambient/habitual dietary conditions. Therefore, we assessed if
fasting hepatic DNL during habitual dietary conditions may be
inferred from circulating FA markers in different lipid fractions.
Methods
Subjects from 5 different cohorts were pooled, giving a total
of 149 men and women who all had fasting DNL in VLDL-
TG assessed with stable-isotopes; Supplemental Figure 1. A
subgroup of 21 males also had newly synthesized palmitate
assessed in total plasma TG, plasma cholesteryl esters (CE),
plasma phospholipids (PL), and red blood cell (RBC) PL. The
21 healthy males were recruited from the Oxford BioBank (ww
w.oxfordbiobank.org.uk) (15). All volunteers were considered
nondiabetic and free from any known disease, were not taking
medication known to affect lipid or glucose metabolism, and
did not consume alcohol above recommended limits. Participants
were considered to have low or high fasting hepatic DNL based
on whether they were below or above the group median of 6.5%.
All studies were approved by the respective Research Ethics
Committees, and all subjects gave written informed consent.
Some, but not all, of the data reported in this work constitute a
reanalysis of previously published studies (16, 17).
Body composition
Whole-body composition and fat distribution were measured
using dual-energy X-ray absorptiometry (18).
Measurements of DNL
Before the measurement of fasting hepatic DNL, subjects were
asked to avoid alcohol and strenuous exercise, and a fasting blood
sample was taken to measure background isotopic enrichment
in plasma water and VLDL-TG. The evening before the study
day (∼12 h before assessment), subjects consumed 2H2O (3 g/kg
body water) and continued to consume enriched water (2.5 g
per 500 mL of water) over the course of the evening, in order
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FIGURE 2 Correlations (Spearman rho) between fatty acid markers in VLDL-TG and fasting hepatic DNL. n = 149 for all except 14:0 (n = 134) and
18:1n–7 (n = 67). DNL, de novo lipogenesis; Rho, rank correlation coefficient; SCD, stearoyl-CoA desaturase; VLDL-TG, very low-density lipoprotein-
triglyceride.
to achieve and maintain a plasma water enrichment of 0.3%.
Based on the previous work by Diraison et al. (19), which clearly
demonstrated that within 4 h of a participant being given loading
doses of 2H2O, an enrichment plateau of deuterium in plasma
water was achieved, it is likely that subjects in the present study
achieved and maintained an enrichment plateau of deuterium in
plasma water. Subjects were advised to consume a low-fat dinner
the evening before measurement of DNL. After an overnight fast,
D
ow
nloaded from
 https://academ
ic.oup.com
/ajcn/article-abstract/109/2/260/5307131 by U
niversity of Surrey user on 28 O
ctober 2019
Assessing fasting hepatic DNL using proxy markers 263
TABLE 2 Fasting fatty acid composition (mol %) of very low-density
lipoprotein-triglyceride in individuals classified as having low and high
fasting hepatic DNL1
Low DNL
(n = 75)
High DNL
(n = 74)
Lipogenic Index
(16:0/18:2n–6)
1.66 ± 0.09 1.87 ± 0.08
Stearoyl-CoA desaturase Index
(16:1n–7/16:0)
0.15 ± 0.01 0.16 ± 0.01
14:0 1.5 ± 0.07 2.1 ± 0.11∗∗∗
16:0 25.5 ± 0.36 26.4 ± 0.48†
16:1n–7 4.2 ± 0.19 4.1 ± 0.18
18:0 3.0 ± 0.14 3.4 ± 0.11∗∗
18:1n–9 44.5 ± 0.62 43.3 ± 0.64
18:1n–7 2.7 ± 0.12 2.7 ± 0.08
18:2n–6 15.3 ± 0.47 14.3 ± 0.43
1Data presented as medians ± SEMs. †P = 0.08, ∗∗P < 0.001;
∗∗∗P < 0.001 low DNL compared with high DNL. Differences were
analyzed using Mann–Whitney U-test. Low/high DNL groups based on
lower/higher than median DNL in all subjects. DNL, de novo lipogenesis.
subjects came to the Clinical Research Unit, and a blood sample
was taken.
Analytical methods
Whole blood was collected into heparinized syringes (Sarst-
edt), and plasma was rapidly separated by centrifugation at 4◦C
for measurement of plasma FA composition, plasma metabolites
were analyzed enzymatically, and insulin was measured by
radioimmunoassay [Millipore (UK) Ltd] (20). After removal
of plasma, the upper buffy coat was removed, and the packed
erythrocytes were washed as described (21) and stored at −80◦C
for the analysis of RBC total PL FAs.
Separation of the VLDL-rich fraction (Sf20–400) was made
by sequential flotation using density gradient ultracentrifugation
(22, 23), although for 1 study (16), VLDL1 and VLDL2 were
isolated from plasma using density-gradient ultracentrifugation
(24). Because the calculated DNL in VLDL1 and VLDL2 were
similar, we have used the data for DNL in VLDL1.
Fatty acid composition, indexes, and isotopic enrichment
FA methyl esters (FAMEs) were prepared from the VLDL-
TG fraction (22, 23) and plasma PL, CE, TG, and RBC (25–
27). FA relative abundance (mol%) was determined by gas
chromatography (GC) (28).
The ratio of palmitic acid (16:0) to linoleic acid (18:2n–6)
[lipogenic index (29)] in the respective blood lipid fractions was
used as an index of hepatic DNL and the ratio of palmitoleic acid
(16:1n–7) to palmitic acid (16:0) (SCD index) as a marker of
stearoyl-CoA desaturase (SCD) activity (30).
Fasting hepatic DNL was assessed based on the incorporation
of deuterium from 2H2O in plasma water (Finnigan GasBench-
II, ThermoFisher Scientific) into VLDL-TG palmitate along with
the incorporation of deuterium from 2H2O in plasma water into
total plasma TG, CE, PL, and RBC PL palmitate using GC-MS
with monitoring ions with mass-to-charge ratios (m/z) of 270
(M+ 0) and 271 (M+ 1) (31). The percentage “DNL” represents
the synthesis of palmitate from nonlipid precursors (1).
Statistics
Data were analyzed using JMP 13.1.0 (SAS Institute Inc.).
Data are presented as median (IQR) or mean± SD. Comparisons
of DNL with the different lipid fraction parameters were
assessed using a Wilcoxon-signed rank test. Differences between
subgroups were analyzed using the t-test or Mann–Whitney
U-test. Associations between variables were carried out using
Spearman’s rank correlation coefficient. Multiple regression
analyses were performed with BMI, visceral fat, and HOMA-IR
as covariates. P < 0.05 was considered statistically significant.
The primary outcome of the present study was to investigate
the associations between fasting hepatic DNL and proposed fatty
acid markers of DNL in VLDL-TG.
Results
Subject characteristics are shown in Table 1 and the dis-
tribution of DNL in Figure 1. Fasting hepatic DNL was not
different (P= 0.83) between males [6.71% (3.87–11.85) median
(interquartile range)] and females [6.23% (3.34–11.40) median
(interquartile range)]. The median age and BMI of the whole
cohort were 47 y (range 23–67 y) and 27.3 kg/m2 (range 19.5–
39.5 kg/m2), and the fasting hepatic DNL was 6.5% (range
0.1–38.7%). We classified individuals as having high [n = 74
(n = 41 females)] and low [n = 75 (n = 44 females)] fasting
hepatic DNL based on the median of 6.5%. There was no
difference in age between the groups, but the high DNL group
had significantly (P < 0.05 for all) higher BMI, plasma insulin,
and TG concentrations than the low DNL group (Table 1). The
biochemical and clinical variables most strongly associated with
fasting hepatic DNL were fasting insulin (r= 0.39, P= 0.0001),
fasting TG (r = 0.41, P = 0.0001), and waist circumference
(r = 0.35, P = 0.0001). BMI (r = 0.21, P = 0.009), body fat
(r = 0.20, P = 0.02), and visceral fat (r = 0.21, P = 0.027)
were only weakly associated. Age, glucose, nonesterified fatty
acids, and total cholesterol were not associated, whereas HDL
cholesterol was inversely associated (r = −0.26, P = 0.001).
Fasting hepatic DNL and associations with fatty acid
markers
Because FA ratios (lipogenic and SCD index) and/or specific
FAs are often used to infer hepatic DNL, we assessed whether
these were associated with DNL in VLDL-TG. We found that
neither the lipogenic index nor the SCD index was significantly
associated with DNL in VLDL-TG (Figure 2). Because the FAs
14:0, 16:1n–7, 18:0, 18:1n–9, and 18:1n–7 have been suggested
to be part of the DNL pathway (3, 4, 6, 9), we assessed the
association between DNL and the abundance of specific FAs in
VLDL-TG (Figure 2). We found the relative abundance (mol%)
of 14:0, 16:0, and 18:0 to be weakly/moderately positively
associated with DNL, whereas 16:1n–7, 18:1n–9, and 18:1n–7
were not associated with DNL (Figure 2).
Fasting DNL and fatty acid markers: subgroup analysis
To investigate if FA markers could be used to discriminate
between subjects with high DNL and those with low DNL, we
divided the cohort by median DNL and compared the groups.
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FIGURE 3 Correlations (Spearman rho) between fatty acid markers in VLDL-TG and fasting hepatic DNL in subgroups split by median fasting hepatic
DNL. “High DNL” denoted by filled triangle, “Low DNL” denoted by open circle. n = 74/75 for High/Low DNL except for 14:0 (n = 67/67) and 18:1n–7
(n= 29/38). DNL, de novo lipogenesis; Rho, rank correlation coefficient; SCD, stearoyl-CoA desaturase; VLDL-TG, very low-density lipoprotein-triglyceride.
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TABLE 3 Multiple regression analysis between hepatic de novo
lipogenesis and fatty acid markers after adjusting for potential confounding
variables (BMI, visceral fat, and homeostatic model assessment of insulin
resistance)
β P value
Lipogenic Index (16:0/18:2n–6) 1.69 0.11
Stearoyl-CoA desaturase Index
(16:1n–7/16:0)
− 2.22 0.87
14:0 2.59 0.008
16:0 0.34 0.094
16:1n–7 0.25 0.59
18:0 0.32 0.61
18:1n–9 − 0.1 0.44
18:1n–7 0.33 0.78
18:2n–6 − 0.35 0.09
The VLDL-TG lipogenic and SCD indexes were not different
between individuals classified as having high and those with low
fasting hepatic DNL (Table 2). Proportions of 14:0 and 18:0
in VLDL-TG were higher in subjects with higher than in those
with lower DNL, whereas proportions of 16:0, 16:1n–7, 18:1n–
9, and 18:1n–7 were not different between groups (Table 2).
We assessed the associations between DNL and FA markers in
the respective groups and found that correlations were stronger
in subjects classified as having higher than in those with lower
hepatic DNL (Figure 3).
Because the subgroups differed in characteristics (Table 1),
the results could potentially be confounded; therefore we also
performed a regression analysis in the full cohort adjusting for
BMI, visceral fat, and insulin resistance (HOMA-IR) (Table 3).
The proportion of 14:0 in VLDL-TG remained significantly
associated with hepatic DNL, such that a 1% increase in VLDL-
TG 14:0 abundance was associated with a 2.59% increase in
DNL. The proportion of 18:0 in VLDL-TG was no longer
significant after adjustment, and the other FA markers remained
nonsignificant (Table 3). Although the abundances of 14:0, 16:0,
and 18:0 in VLDL-TG were significantly associated with DNL
in unadjusted analyses (Figure 2), the diagnostic values were
poor. If “high DNL” (top quartile) was “diagnosed” using FA
abundance (top quartile), the predictive values were 52% for 14:0,
41% for 16:0, and 38% for 18:0, respectively. Similarly, if “low
DNL” (bottom quartile) was “diagnosed” using FA abundance
(bottom quartile), the predictive values were 32% for 14:0, 24%
for 16:0, and 37% for 18:0, respectively.
Use of other blood lipid fractions to assess fasting DNL
As plasma VLDL-TG is not measured in a large proportion
of studies, we investigated whether other more commonly used
blood lipid fractions could be used to assess fasting hepatic DNL.
In a subgroup of n = 21 males, DNL was measured in VLDL-
TG, total plasma TG, CE, PL, and RBC PL while consuming
their habitual diet. When compared with DNL in VLDL-TG,
which was 13.7 ± 7.9% (mean ± SD), we found it to be
significantly lower in all other fractions: 10.2 ± 9.3% in total
plasma TG, 1.3 ± 2.1% in plasma CE, 4.2 ± 3.2% in plasma
PL, and 2.7 ± 3.2% in RBC PL, all P ≤ 0.002 compared with
VLDL-TG (Figure 4). Finally, we investigated the associations
between the proposed FA markers in these other fractions with
DNL and found no significant associations for the lipogenic
or SCD indexes in any fraction (Table 4). Specific FAs were
generally not associated with DNL, except for 18:0 showing
positive associations (Figure 4).
Discussion
Ideally, hepatic DNL ismeasured using stable-isotopemethod-
ologies, but, for practical reasons, as proxy markers circulating
FAs or FA ratios are often measured. However, it remains unclear
how reflective these markers are of hepatic DNL during habitual
dietary conditions, so we investigated the association between
fasting hepatic DNL (assessed in VLDL-TG using stable-isotope
methodologies) and circulating FA markers that are often used
to infer hepatic DNL in healthy individuals consuming their
habitual diet. We did not find any strong associations between FA
markers and DNL, and diagnostic values were poor, suggesting
that fasting hepatic DNL in subjects consuming their habitual diet
is not reliably inferred from commonly used FA proxies.
DNL is an insulin-mediated process, and we have pre-
viously reported higher DNL in hyperinsulinemic than in
normoinsulinemic individuals (11). In the present study, plasma
insulin concentrations were positively associated with fasting
DNL.
Large observational studies have assessed the relation between
individual FAs and FA ratios with outcomes such as NAFLD
or T2D (3, 6) and found that the RBC lipogenic index and
16:1n–7 tended to be positively associated with a fatty liver
index (FLI) (3). In the present study, we found no association
between fasting DNL in VLDL-TG and the lipogenic and SCD
indexes or abundance of 16:1n–7 in VLDL-TG. The lack of
association between DNL and the lipogenic index is in agreement
with Lee et al. (9), although, in contrast to our findings, they
observed strong positive associations between DNL, the SCD
index, and the relative abundance of 16:1n–7 in VLDL-TG (9).
Dissociation between DNL and the SCD index has previously
been reported (11, 16, 32). We have previously calculated an
isotopic desaturation index in VLDL-TG and found a significant
correlation with DNL (16), suggesting the isotopic index may be
more relevant as a marker of overnight fasting FA desaturation
than a nonisotopic index.
Our results are partly in agreement with earlier work (13, 29).
In a study of 10 healthy subjects, Hudgins et al. (29) fed liquid
formula diets either high (40% total energy (TE), n = 3) or low
(10% TE, n = 7) in fat, with matched FA composition, for 25
d. They found that the proportions of 14:0, 16:0, and 16:1 in
VLDL-TG were all higher on the low-fat diet than on the high-
fat diet, whereas the proportions of 18:0, 18:1n–9, and 18:1n–7
did not appear to be differentially affected. Hudgins et al. (13)
later replicated some of this work using solid-food diets (given
for 2 wk) and found that the proportion of 16:0, but not 18:1n–9,
was higher in VLDL-TG after a low-fat (10% TE) than after a
high-fat (30% TE) diet in both lean and obese subjects. These
data suggest that in order to see a change in FA composition
that would be reflective of hepatic DNL, there needs to be a
provocation or stimulus, such as a low-fat, high-carbohydrate
diet (34).
In humans, tissue and blood FAs are reflective of dietary
FA intake (35), but the proportion of carbohydrate in the diet
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FIGURE 4 Percentage newly synthesized palmitate in circulating VLDL-TG, total plasma TG, plasma CE, plasma PL, and RBC PL. n = 21 men for all
fractions. ∗P < 0.05, ∗∗∗P < 0.001 compared with VLDL-TG; analyzed using Wilcoxon-signed rank test. CE, cholesteryl esters; DNL, de novo lipogenesis;
PL, phospholipids; RBC, red blood cells; TG, triglyceride; VLDL-TG, very low-density lipoprotein-triglyceride.
can influence hepatic DNL (2, 13, 29). We previously found
that short-term consumption (3 d) of a high-carbohydrate diet
increased both the lipogenic and SCD indexes in VLDL-TG
compared with a lower carbohydrate diet (33). Although changes
in dietary fat composition are reflected by the FA composition
of blood lipid fractions within days (25), it remains unclear
how rapidly changes in DNL FAs are reflected. Compared with
VLDL-TG, we found significantly lower DNL in plasma TG,
CE, PL, and RBC PL, which may be due to longer turnover
times. VLDL-TG contributes greater than 50% of total plasma
TG in healthy individuals (36); however, DNL in this fraction
was significantly lower than VLDL-TG, which may be explained
by dilution from TG present in other circulating lipoproteins. We
found evidence for DNL in the plasma PL fraction, and although
de novo FAs have been suggested to be incorporated into PL
to a greater extent than exogenous FAs (37), the complexities
of PL synthesis along with known enzyme specificities make
it unclear if measuring markers of de novo FAs would clearly
discriminate between individuals with high and low hepatic
DNL.
DNL was lowest in plasma CE, which may be due to the
specificities of the intracellular enzyme responsible for CE
formation (35). The CE fraction comprises <5% of total liver
FAs (38), and because CE formation is not liver-specific, it is
likely that the plasmaCE fraction is not reflective of hepatic DNL.
It has previously been suggested under lipogenic conditions
TABLE 4 Correlation coefficients between hepatic de novo lipogenesis and fatty acid markers in other blood lipid
fractions1
Fasting hepatic de novo lipogenesis
Plasma
triglycerides
Plasma cholesteryl
esters
Plasma
phospholipids
Red blood cell
phospholipids
Lipogenic Index (16:0/18:2n–6) 0.16 0.10 − 0.04 0.24
Stearoyl-CoA desaturase Index
(16:1n–7/16:0)
− 0.15 0.22 0.04 − 0.23
14:0 0.21 − 0.27 0.13 − 0.01
16:0 0.12 0.04 − 0.35 0.09
16:1n–7 − 0.07 0.12 − 0.03 − 0.25
18:0 0.46 0.46∗ 0.73∗ 0.64∗
18:1n–9 − 0.17 0.24 0.57∗ 0.27
18:1n–7 − 0.50∗ − 0.23 − 0.34 0.02
1n = 21 men for all fractions. Correlation coefficients are Spearman rho. ∗P < 0.05. Rho, rank correlation
coefficient.
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that only 2–3% of newly synthesized palmitate is secreted as
VLDL-CE and -PL (39). In contrast, RBCs are incapable of de
novo PL synthesis, chain elongation, or desaturation (40, 41),
so the appearance of any newly synthesized palmitate would
occur by direct exchange of phosphatidylcholine (PC) from
plasma lipoproteins to the RBC membrane (42) and acylation
of lysophospholipids, which are formed in the membrane or
derived from surrounding plasma (43). Changes in dietary FA
intakes are reflected in the FA composition of RBC PC within
days (44), so it is plausible that the appearance of newly
synthesized palmitate occurred as a result of direct and rapid FA
exchange.
Our study has some limitations. Dietary intakes were not
standardized or assessed on the days before the study visit, and it
is possible that some subjects made acute dietary changes before
the study day; however, this setting is the reality for the majority
of cohorts inferring DNL from circulating FA markers. Because
we measured DNL after an overnight fast, we were unable to
assess the synthesis of other DNL FAs as carried out by Wilke
et al. (2), which would be of interest to do because it would help
to clarify what specific FAs may be useful surrogate markers of
hepatic DNL in individuals consuming their habitual diet. The
labeling period may have been too short to accurately quantify
newly synthesized palmitate in lipid fractions other than VLDL-
TG or total plasma TG due to slower turnover. A longer labeling
time could be argued for the assessment of DNL in VLDL-TG
due to a potential delay in secretion of newly formed palmitate.
However, recirculation of labels might result in exaggerated
values of DNL; our protocol for the assessment of DNL is
in line with previous studies (8, 31, 45). It has recently been
reported (46) that labeling with 2H2O for 7–14 d gives higher
DNL values than the shorter-term labeling approaches more
commonly used. The duration of labeling is a trade-off between
cost, feasibility, and the ability to detect delayed secretion of
newly formed palmitate, and the “optimal” duration for labeling
should be further explored. Finally, we only assessed nondiabetic
individuals, so it is plausible that our findings would be different
if we had studied other cohorts such as individuals with
T2D.
The use of FA markers as indirect measurements of DNL from
a single fasting blood sample in participants consuming their
habitual diet may not discriminate reliably between individuals
with low and high hepatic DNL. Therefore, to disentangle the
origin (dietary or endogenously synthesized) of FAs in blood
lipid fractions, gold-standard stable-isotope tracer methods are
required.
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